tetano
Editor, Senior Moderator
J Clin Neurol
. 2023 Mar 13.
doi: 10.3988/jcn.2022.0348. Online ahead of print.
Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
Ning Liu[SUP] #[/SUP][SUP] 1 [/SUP], WuHan Yu[SUP] #[/SUP][SUP] 2 [/SUP], Mengjiao Sun[SUP] 1 [/SUP], Wenjing Zhang[SUP] 1 [/SUP], Dan Zhou[SUP] 1 [/SUP], Jing Sun[SUP] 1 [/SUP], ManXia Wang[SUP] 3 [/SUP]
Affiliations
Abstract
Background and purpose: A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs).
Methods: Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: ("multiple sclerosis" OR "MS") AND ("DMT" OR "disease modifying therapies") AND ("COVID-19"). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software.
Results: 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13-0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63-4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs.
Conclusions: In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic.
Keywords: COVID-19; disease-modifying therapies; multiple sclerosis; prognosis.
. 2023 Mar 13.
doi: 10.3988/jcn.2022.0348. Online ahead of print.
Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis
Ning Liu[SUP] #[/SUP][SUP] 1 [/SUP], WuHan Yu[SUP] #[/SUP][SUP] 2 [/SUP], Mengjiao Sun[SUP] 1 [/SUP], Wenjing Zhang[SUP] 1 [/SUP], Dan Zhou[SUP] 1 [/SUP], Jing Sun[SUP] 1 [/SUP], ManXia Wang[SUP] 3 [/SUP]
Affiliations
- PMID: 36929061
- DOI: 10.3988/jcn.2022.0348
Abstract
Background and purpose: A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs).
Methods: Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: ("multiple sclerosis" OR "MS") AND ("DMT" OR "disease modifying therapies") AND ("COVID-19"). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software.
Results: 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13-0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63-4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs.
Conclusions: In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic.
Keywords: COVID-19; disease-modifying therapies; multiple sclerosis; prognosis.